Bosch and colleagues searched MEDLINE for studies published in English between 1966 and 2007 that evaluated the available treatments for antineutrophil cytoplasmic antibody (ANCA)-associated ...

Identification of risk factors for relapse of ANCA-associated small-vessel vasculitis would allow therapy ... of resistance also rose with severity of kidney disease. Of the patients who attained ...

Therapeutic plasma exchange (TPE) may not prevent end stage renal disease (ESRD) or improve remission and mortality rates in patients with antineutrophil cytoplasmic antibody (ANCA)-associated ...

Medscape Medical News, October 08, 2024 Frailty Outweighs Age in Predicting ANCA Vasculitis Outcomes Frailty emerged as an independent risk factor for severe infection and end-stage renal disease ...

with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis being the most common. 1,2 Other, less common causes of pulmonary–renal syndrome include anti–glomerular basement ...

Rituximab may be an effective therapeutic option in the management of severe necrotizing scleritis associated with AAV.

Alaska Native and American Indian adults have a high prevalence of AAV, with distinct clinical characteristics and treatment patterns observed.

Birmingham Vasculitis Activity Scores (BVAS) were used to identify disease manifestations. Key efficacy outcomes included remission at week 26, sustained remission at week 52, relapse rates, the ...

An improved renal prognosis in patients with RPGN would decrease ... targeting the pan-B-cell marker CD20 for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (covered since 2013), ...

Chronic Kidney Disease Poses Challenges in Latin ... Medscape Medical News, March 04, 2024 Updated ANCA Vasculitis Guideline Aims to Improve Care The KDIGO updates addressed the "unprecedented ...